Tsuyoshi Yokoi

Q: What Schools Are Affiliated With Tsuyoshi Yokoi

Tsuyoshi Yokoi is affiliated with the following schools: Hokkaido University, Kanazawa University, University of Tokyo, Nagoya University, Institute of Science Tokyo, Kyoto University

Tsuyoshi Yokoi's AcademicInfluence.com Rankings

Tsuyoshi Yokoi

Computer Science

#8212

World Rank

#8634

Historical Rank

Computational Linguistics

#1791

World Rank

#1809

Historical Rank

Machine Learning

#3297

World Rank

#3336

Historical Rank

Artificial Intelligence

#3601

World Rank

#3652

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Tsuyoshi Yokoi's Degrees

PhD Computer Science University of Tokyo
Masters Computer Science University of Tokyo
Bachelors Computer Science University of Tokyo

Similar Degrees You Can Earn

Why Is Tsuyoshi Yokoi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Tsuyoshi Yokoi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cytochrome P450-mediated metabolism of estrogens and its regulation in human. (2005) (530)
Near completely humanized liver in mice shows human-type metabolic responses to drugs. (2004) (512)
Role of human cytochrome P4502A6 in C-oxidation of nicotine. (1996) (434)
MicroRNA regulates the expression of human cytochrome P450 1B1. (2006) (407)
Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. (1996) (347)
Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. (1999) (346)
Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. (2002) (315)
Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines (2008) (299)
Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. (1996) (291)
Post-transcriptional Regulation of Human Pregnane X Receptor by Micro-RNA Affects the Expression of Cytochrome P450 3A4* (2008) (275)
Human CYP1B1 is regulated by estradiol via estrogen receptor. (2004) (247)
Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. (2002) (245)
Quantitative Analysis of UDP-Glucuronosyltransferase (UGT) 1A and UGT2B Expression Levels in Human Livers (2009) (242)
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations (2006) (224)
MicroRNA regulates human vitamin D receptor (2009) (192)
Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. (2000) (186)
The emerging role of human esterases. (2012) (177)
Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. (2004) (177)
A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. (2000) (172)
Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans (2001) (168)
Human CYP2E1 is regulated by miR-378. (2010) (168)
Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences (2002) (167)
A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. (2015) (167)
Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins (2010) (160)
Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. (1999) (159)
MicroRNAs Regulate Human Hepatocyte Nuclear Factor 4α, Modulating the Expression of Metabolic Enzymes and Cell Cycle* (2009) (157)
Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug–drug interactions (2000) (152)
Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. (1994) (150)
Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. (2001) (143)
Human CYP2A6 Is Induced by Estrogen via Estrogen Receptor (2007) (142)
Effects of polymorphism in Promoter Region of Human CYP2A6 Gene (CYP2A6*9) on Expression Level of Messenger Ribonucleic Acid and Enzymatic Activity In Vivo and In Vitro (2003) (138)
Human CYP24 Catalyzing the Inactivation of Calcitriol Is Post-Transcriptionally Regulated by miR-125b (2009) (138)
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients (2007) (129)
Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans (2000) (127)
A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. (2004) (126)
Detection of Three Genetic Polymorphisms in the 5′‐Flanking Region and Intron 1 of Human CYP1A2 in the Japanese Population (1999) (124)
Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. (2004) (119)
PPARα Is Regulated by miR-21 and miR-27b in Human Liver (2011) (118)
Establishment and Characterization of the Transformants Stably-Expressing MDR1 Derived from Various Animal Species in LLC-PK1 (2006) (116)
A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). (1998) (114)
microRNAs as mediators of drug toxicity. (2013) (113)
Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats (1998) (111)
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. (2002) (111)
Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. (2006) (110)
Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. (2013) (109)
Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. (2011) (108)
EXPRESSION OF HUMAN CYTOCHROMES P450 IN CHIMERIC MICE WITH HUMANIZED LIVER (2004) (104)
A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. (1999) (103)
Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. (2005) (102)
Nicotine metabolism and CYP2A6 allele frequencies in Koreans. (2001) (98)
Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. (2000) (98)
Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. (2003) (96)
Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. (2001) (95)
EXPRESSION OF HUMAN PHASE II ENZYMES IN CHIMERIC MICE WITH HUMANIZED LIVER (2005) (94)
IDENTIFICATION OF THE CYTOSOLIC CARBOXYLESTERASE CATALYZING THE 5′-DEOXY-5-FLUOROCYTIDINE FORMATION FROM CAPECITABINE IN HUMAN LIVER (2004) (93)
Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. (2004) (92)
Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. (1999) (90)
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo (2004) (89)
Expression of aryl hydrocarbon receptor repressor in normal human tissues and inducibility by polycyclic aromatic hydrocarbons in human tumor-derived cell lines. (2003) (88)
In Vitro Evaluation of Inhibitory Effects of Antidiabetic and Antihyperlipidemic Drugs on Human Carboxylesterase Activities (2010) (88)
Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. (2003) (85)
Inhibitory Potencies of 1,4-dihydropyridine Calcium Antagonists to P-glycoprotein-Mediated Transport: Comparison with the Effects on CYP3A4 (2000) (85)
CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS (2005) (84)
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. (2001) (84)
Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. (2002) (83)
Species Differences in UDP-Glucuronosyltransferase Activities in Mice and Rats (2008) (83)
Effects of Coexpression of UGT1A9 on Enzymatic Activities of Human UGT1A Isoforms (2007) (83)
Toxicological implications of modulation of gene expression by microRNAs. (2011) (82)
Plasma MicroRNA Profiles in Rat Models of Hepatocellular Injury, Cholestasis, and Steatosis (2012) (81)
Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. (2003) (80)
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. (2007) (80)
Chimeric mice with humanized liver. (2008) (79)
Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes (2008) (79)
Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes (2000) (78)
Genetic polymorphisms of CYP2C8 in Japanese population. (2003) (78)
Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. (2007) (78)
Interactions between Human UGT1A1, UGT1A4, and UGT1A6 Affect Their Enzymatic Activities (2007) (77)
Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. (2002) (76)
Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. (2008) (76)
CYP2A13 expressed in human bladder metabolically activates 4‐aminobiphenyl (2006) (75)
Human Arylacetamide Deacetylase Is a Principal Enzyme in Flutamide Hydrolysis (2009) (74)
Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. (2002) (74)
Induction of Human CYP2A6 Is Mediated by the Pregnane X Receptor with Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α (2006) (74)
Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes. (1999) (74)
CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. (1996) (73)
INTERINDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM AND GENETIC POLYMORPHISMS OF HUMAN CYP2A6 (2002) (73)
Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. (2000) (73)
Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. (1999) (72)
Screening of Specific Inhibitors for Human Carboxylesterases or Arylacetamide Deacetylase (2014) (71)
Improved highly sensitive method for determination of nicotine and cotinine in human plasma by high-performance liquid chromatography. (2000) (70)
In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. (2000) (69)
Pharmacokinetics of Paclitaxel in Ovarian Cancer Patients and Genetic Polymorphisms of CYP2C8, CYP3A4, and MDR1 (2005) (69)
Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. (2005) (69)
Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. (2007) (66)
Halothane-induced liver injury is mediated by interleukin-17 in mice. (2009) (65)
Arylacetamide Deacetylase Is a Determinant Enzyme for the Difference in Hydrolase Activities of Phenacetin and Acetaminophen (2010) (65)
Glucuronidation of Thyroxine in Human Liver, Jejunum, and Kidney Microsomes (2007) (63)
MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. (2011) (62)
Species Differences in Tissue Distribution and Enzyme Activities of Arylacetamide Deacetylase in Human, Rat, and Mouse (2012) (61)
Different Inhibitory Effects in Rat and Human Carboxylesterases (2009) (60)
A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. (1996) (60)
Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. (2010) (59)
Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. (1993) (59)
Inhibition of benzo[a]pyrene-induced mutagenesis by (-)-epigallocatechin gallate in the lung of rpsL transgenic mice. (1999) (58)
Humanization of excretory pathway in chimeric mice with humanized liver. (2007) (58)
CHARACTERIZATION OF NOVEL CYP2A6 POLYMORPHIC ALLELES (CYP2A6*18 AND CYP2A6*19) THAT AFFECT ENZYMATIC ACTIVITY (2005) (57)
Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation. (2004) (57)
TRANS-3′-HYDROXYCOTININE O- AND N-GLUCURONIDATIONS IN HUMAN LIVER MICROSOMES (2005) (57)
Effects of silver nanoparticles on rat hepatic cytochrome P450 enzyme activity (2012) (56)
Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. (2012) (56)
Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver (2005) (56)
Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1. (2000) (55)
Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. (2002) (55)
Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. (1997) (55)
Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. (2012) (55)
A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. (2005) (54)
Human UDP-Glucuronosyltransferase (UGT) 2B10 in Drug N-Glucuronidation: Substrate Screening and Comparison with UGT1A3 and UGT1A4 (2013) (54)
IN VIVO INDUCTION OF HUMAN CYTOCHROME P450 ENZYMES EXPRESSED IN CHIMERIC MICE WITH HUMANIZED LIVER (2005) (53)
Rat liver flavin-containing monooxygenase (FMO): cDNA cloning and expression in yeast. (1993) (53)
Development of a Highly Sensitive Cytotoxicity Assay System for CYP3A4-Mediated Metabolic Activation (2011) (52)
Novel human CYP2A6 alleles confound gene deletion analysis (2004) (51)
A Novel Duplication Type of CYP2A6 Gene in African-American Population (2007) (50)
A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. (1999) (49)
Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. (2012) (49)
Establishment of transgenic mice carrying human fetus-specific CYP3A7. (1996) (49)
Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. (2009) (48)
Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins. (1995) (48)
Application of Chimeric Mice with Humanized Liver for Predictive ADME (2007) (48)
Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. (2001) (47)
Toxicological Evaluation of Acyl Glucuronides of Nonsteroidal Anti-Inflammatory Drugs Using Human Embryonic Kidney 293 Cells Stably Expressing Human UDP-Glucuronosyltransferase and Human Hepatocytes (2011) (46)
CYP2A13 Metabolizes the Substrates of Human CYP1A2, Phenacetin, and Theophylline (2007) (45)
Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. (2006) (44)
N-Glycosylation plays a role in protein folding of human UGT1A9. (2010) (44)
CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay (2011) (43)
CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. (2002) (42)
Structure and Protein–Protein Interactions of Human UDP-Glucuronosyltransferases (2016) (42)
Retinoid X receptor α in human liver is regulated by miR-34a. (2014) (42)
Prilocaine- and Lidocaine-Induced Methemoglobinemia Is Caused by Human Carboxylesterase-, CYP2E1-, and CYP3A4-Mediated Metabolic Activation (2013) (41)
Product Inhibition of UDP-Glucuronosyltransferase (UGT) Enzymes by UDP Obfuscates the Inhibitory Effects of UGT Substrates (2008) (41)
Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. (2011) (40)
Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes (2003) (39)
Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. (2007) (39)
Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. (2005) (38)
Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. (2012) (38)
Isoflavones Inhibit Nicotine C‐Oxidation Catalyzed by Human CYP2A6 (2006) (38)
CYP2A7 Pseudogene Transcript Affects CYP2A6 Expression in Human Liver by Acting as a Decoy for miR-126* (2015) (37)
Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2). (2010) (37)
An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. (2010) (37)
Toxicological potential of acyl glucuronides and its assessment. (2017) (37)
Genetic polymorphisms in the 5′-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation (2008) (36)
Stereoselective Glucuronidation of 5-(4′-Hydroxyphenyl)-5-phenylhydantoin by Human UDP-Glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: Effects of UGT-UGT Interactions (2007) (36)
Contributions of Arylacetamide Deacetylase and Carboxylesterase 2 to Flutamide Hydrolysis in Human Liver (2012) (36)
Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. (2015) (36)
Human UDP-Glucuronosyltransferase Isoforms Involved in Haloperidol Glucuronidation and Quantitative Estimation of Their Contribution (2012) (36)
In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver (2005) (35)
A Novel Polymorphic Allele of Human Arylacetamide Deacetylase Leads to Decreased Enzyme Activity (2012) (35)
Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. (1999) (35)
Human Paraoxonase 1 Is the Enzyme Responsible for Pilocarpine Hydrolysis (2011) (34)
Induction of cytochrome P450 1B1 in lung, liver and kidney of rats exposed to diesel exhaust. (2001) (34)
Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability. (2008) (34)
Interleukin-17 is involved in alpha-naphthylisothiocyanate-induced liver injury in mice. (2010) (34)
Genetic polymorphism of CYP2D6 in the Japanese population. (1999) (34)
Th2 cytokine‐mediated methimazole‐induced acute liver injury in mice (2012) (33)
Human α/β Hydrolase Domain Containing 10 (ABHD10) Is Responsible Enzyme for Deglucuronidation of Mycophenolic Acid Acyl-glucuronide in Liver* (2012) (33)
Knock Down of γ-Glutamylcysteine Synthetase in Rat Causes Acetaminophen-induced Hepatotoxicity* (2007) (33)
IL-4 mediates dicloxacillin-induced liver injury in mice. (2011) (32)
Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. (2002) (32)
Metabolic Activation of Benzodiazepines by CYP3A4 (2009) (32)
Epigenetic Regulation Is a Crucial Factor in the Repression of UGT1A1 Expression in the Human Kidney (2013) (31)
Epigenetic regulation of the tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10. (2014) (31)
Progesterone Receptor Membrane Component 1 Modulates Human Cytochrome P450 Activities in an Isoform-Dependent Manner (2011) (31)
Estradiol and progesterone modulate halothane-induced liver injury in mice. (2011) (31)
Stable expression of human CYP2E1 in Chinese hamster cells: high sensitivity to N,N-dimethylnitrosamine in cytotoxicity testing. (1996) (31)
Evaluation and Mechanistic Analysis of the Cytotoxicity of the Acyl Glucuronide of Nonsteroidal Anti-Inflammatory Drugs (2014) (30)
Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro (2000) (30)
Allyl isothiocyanate (AITC) inhibits pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation and protects against acetaminophen- and amiodarone-induced cytotoxicity (2014) (30)
Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. (2005) (30)
Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. (2014) (30)
Carbamazepine-Induced Liver Injury Requires CYP3A-Mediated Metabolism and Glutathione Depletion in Rats (2015) (30)
Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity. (2009) (29)
Role of the aryl hydrocarbon receptor and Cyp1b1 in the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (2004) (29)
Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. (1999) (29)
Involvement of Th2 cytokines in the mouse model of flutamide‐induced acute liver injury (2012) (29)
Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines. (2004) (29)
New allelic arrangement CYP2D6*36 x 2 found in a Japanese poor metabolizer of debrisoquine. (2002) (28)
Bezafibrate induces multidrug‐resistance P‐Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice (2007) (28)
Method for determining monohydroxybenzo[a]pyrene isomers using column-switching high-performance liquid chromatography. (2003) (28)
A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. (2016) (28)
In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9. (2009) (27)
Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats (2018) (27)
Mechanism of exacerbative effect of progesterone on drug-induced liver injury. (2012) (27)
Human Hepatocytes Can Repopulate Mouse Liver: Histopathology of the Liver in Human Hepatocyte-Transplanted Chimeric Mice and Toxicologic Responses to Acetaminophen (2008) (27)
Identification of protein disulfide isomerase and calreticulin as autoimmune antigens in LEC strain of rats. (1993) (26)
Inhibitory Effects of Neurotransmitters and Steroids on Human CYP2A6 (2007) (26)
Preparation of a Specific Monoclonal Antibody against Human UDP-Glucuronosyltransferase (UGT) 1A9 and Evaluation of UGT1A9 Protein Levels in Human Tissues (2012) (26)
Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats. (2001) (26)
A novel mouse model for phenytoin-induced liver injury: involvement of immune-related factors and P450-mediated metabolism. (2013) (25)
Key Amino Acid Residues Responsible for the Differences in Substrate Specificity of Human UDP-Glucuronosyltransferase (UGT)1A9 and UGT1A8 (2009) (25)
Cooperativity of α-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human (2001) (25)
Occurrence of autoantibody to protein disulfide isomerase in patients with hepatic disorder. (1994) (25)
Characterization of a novel variant (S145C/L311V) of 3alpha-hydroxysteroid/dihydrodiol dehydrogenase in human liver. (1999) (25)
In vivo activation of aflatoxin B1 in C57BL/6N mice carrying a human fetus-specific CYP3A7 gene. (1997) (25)
Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. (2014) (25)
CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele (2006) (25)
Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway (2011) (24)
Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. (1999) (24)
Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. (2012) (24)
P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice (2014) (24)
Drug-induced hepatotoxicity test using gamma-glutamylcysteine synthetase knockdown rat. (2009) (24)
Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rat. (2009) (24)
Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. (1998) (23)
Glucuronidation of Antiallergic Drug, Tranilast: Identification of Human UDP-Glucuronosyltransferase Isoforms and Effect of Its Phase I Metabolite (2007) (23)
Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. (2015) (23)
Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. (2009) (23)
Rat cytochrome p450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes. (2001) (23)
Regulation of Cytochrome b5 Expression by miR-223 in Human Liver: Effects on Cytochrome P450 Activities (2014) (23)
Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD. (2009) (23)
Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. (2005) (22)
Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway. (2010) (22)
Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. (2006) (22)
Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases. (2005) (22)
Metabolic activation of carcinogenic 1-nitropyrene by human cytochrome P450 1B1 in Salmonella typhimurium strain expressing an O-acetyltransferase in SOS/umu assay. (2001) (21)
Inhibition of UDP‐glucuronosyltransferase by Aglycons of Natural Glucuronides in Kampo Medicines Using SN‐38 as a Substrate (1995) (21)
Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injury. (2014) (21)
Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: Prediction of in vivo drug interactions (2005) (21)
Activation of phenacetin O-deethylase activity by α-naphthoflavone in human liver microsomes (1999) (21)
The citrus flavanone naringenin suppresses CYP1B1 transactivation through antagonising xenobiotic-responsive element binding (2012) (21)
A mutation in the flavin-containing monooxygenase 3 gene and its effects on catalytic activity for N-oxidation of trimethylamine in vitro. (2002) (21)
Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. (2012) (20)
Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450s in SOS/umu assay. (2002) (20)
Change of drug excretory pathway by CCl4-induced liver dysfunction in rat. (2007) (20)
Kupffer cell‐mediated exacerbation of methimazole‐induced acute liver injury in rats (2016) (20)
Toxicological role of an acyl glucuronide metabolite in diclofenac‐induced acute liver injury in mice (2017) (20)
Targeted Screen for Human UDP-Glucuronosyltransferases Inhibitors and the Evaluation of Potential Drug-Drug Interactions with Zafirlukast (2015) (19)
Sex-related differences in the expression of cytochrome P450 in hamsters: cDNA cloning and examination of the expression of three distinct CYP2C cDNAs. (1994) (19)
Genetic Polymorphism of Drug Metabolizing Enzymes: New Mutations in CYP2D6 and CYP2A6 Genes in Japanese (1998) (18)
Establishment of a mouse model for amiodarone‐induced liver injury and analyses of its hepatotoxic mechanism (2016) (18)
Indiplon Is Hydrolyzed by Arylacetamide Deacetylase in Human Liver (2014) (18)
Zomepirac Acyl Glucuronide Is Responsible for Zomepirac-Induced Acute Kidney Injury in Mice (2016) (18)
Regulation of insulin-like growth factor binding protein-1 and lipoprotein lipase by the aryl hydrocarbon receptor. (2008) (18)
Involvement of immune‐ and inflammatory‐related factors in flucloxacillin‐induced liver injury in mice (2015) (18)
Involvement of miRNAs in the early phase of halothane-induced liver injury. (2014) (18)
Immunohistochemical analysis of CYP2A13 in various types of human lung cancers (2010) (17)
Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. (1999) (17)
Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. (1995) (17)
Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. (1998) (17)
[Genetic polymorphism of drug metabolizing enzymes]. (1997) (17)
Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. (2017) (17)
Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. (2018) (17)
Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs. (2012) (16)
Stereoselective pharmacokinetics and interconversions of flosequinan enantiomers containing chiral sulphoxide in rat. (1994) (16)
Knock down of gamma-glutamylcysteine synthetase in rat causes acetaminophen-induced hepatotoxicity. (2007) (15)
miRNA in Rat Liver Sinusoidal Endothelial Cells and Hepatocytes and Application to Circulating Biomarkers that Discern Pathogenesis of Liver Injuries. (2018) (15)
Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine (2008) (15)
Identification of urinary biomarkers useful for distinguishing a difference in mechanism of toxicity in rat model of cholestasis. (2009) (14)
Halothane‐induced hepatitis: Paradigm or paradox for drug‐induced liver injury (2014) (14)
Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. (2012) (14)
An Orphan Esterase ABHD10 Modulates Probenecid Acyl Glucuronidation in Human Liver (2014) (14)
Inhibition of Toll‐like receptor 4 ameliorates experimental postischemic injury in the cholestatic liver through inhibition of high‐mobility group box protein b1 (HMGB1) signaling (2017) (13)
An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury (2020) (13)
Inhibitory effects of Kampo medicine on human UGT2B7 activity. (2009) (13)
Perinatal expression and inducibility of human CYP3A7 in C57BL/6N transgenic mice. (1996) (13)
A modified multiparametric assay using HepaRG cells for predicting the degree of drug‐induced liver injury risk (2017) (13)
A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. (2019) (13)
N-Glycosylation during translation is essential for human arylacetamide deacetylase enzyme activity. (2014) (12)
Role of cytochrome P450-mediated metabolism and involvement of reactive metabolite formations on antiepileptic drug-induced liver injuries. (2018) (12)
Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans. (1997) (12)
Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes. (2002) (12)
Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver. (2008) (12)
Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. (2018) (12)
In Vitro Investigation of the Glutathione Transferase M1 and T1 Null Genotypes as Risk Factors for Troglitazone-Induced Liver Injury (2011) (12)
Expression of CYP3A7, a human fetus-specific cytochrome P450, in cultured cells and in the hepatocytes of p53-knockout mice. (1995) (12)
Models of Idiosyncratic Drug-Induced Liver Injury. (2020) (12)
Interpretation of the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo. (2011) (12)
In vivo detection of mutations induced by aflatoxin B1 using human CYP3A7/HITEC hybrid mice. (1998) (11)
Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. (2016) (11)
Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance (2021) (11)
Occurrence of autoimmune antibodies to liver microsomal proteins in association with fulminant hepatitis in the LEC strain of rats. (1991) (11)
Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS (2018) (10)
Efficient complementary DNA directed expression of human fetal liver cytochrome P450 (CYP3A7) in insect cells using baculovirus. (1995) (10)
Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. (2001) (10)
Establishment of immortal hepatocytes from a CYP3A7-transgenic/p53-knockout mouse. (1995) (10)
S-oxidation of (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidin-4-one hydrochloride by rat hepatic flavin-containing monooxygenase 1 expressed in yeast. (1995) (10)
Effects of Phyllanthus amarus on the pharmacokinetics of midazolam and cytochrome P450 activities in rats (2012) (9)
Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate. (2019) (9)
Molecular cloning and sequence analysis of hamster CYP2E1. (1994) (9)
Evaluation of Expression and Glycosylation Status of UGT1A10 in Supersomes and Intestinal Epithelial Cells with a Novel Specific UGT1A10 Monoclonal Antibody (2017) (9)
Allopurinol induces innate immune responses through mitogen‐activated protein kinase signaling pathways in HL‐60 cells (2016) (9)
Cancer pharmacogenomics: achievements in basic research (2005) (9)
Decrease in the content of cytochrome P450IIE by fasting in liver microsomes of house musk shrew (Suncus murinus). (1992) (9)
Changes in the expression of miRNAs at the pericentral and periportal regions of the rat liver in response to hepatocellular injury: comparison with the changes in the expression of plasma miRNAs. (2014) (9)
Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background. (2019) (9)
Effects of coexpression of UGT 1 A 9 on enzymatic activities of human UGT 1 A isoforms (2007) (9)
Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. (2018) (9)
Decreased responsiveness of naturally occurring mutants of human estrogen receptor α to estrogens and antiestrogens (2006) (9)
Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver (2008) (8)
Inhibition of Cytochrome P450 2C9 Expression and Activity In Vitro by Allyl Isothiocyanate (2014) (8)
Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. (1999) (8)
Post-transcriptional regulation of human pregnane X receptor by microRNA affects the expression of cytochrome P450 3A4 (2008) (8)
High-performance liquid chromatographic assay for N-glucuronidation of nicotine and cotinine in human liver microsomes. (2002) (8)
MicroRNA-mediated Th2 bias in methimazole-induced acute liver injury in mice. (2016) (8)
Effects of cyclosporin-A and D-penicillamine on the development of hepatitis and the production of antibody to protein disulfide isomerase in LEC rats. (1994) (8)
Binding of steroidogenic factor-1 to the regulatory region might not be critical for transcriptional regulation of the human CYP1B1 gene. (2006) (8)
Fluoroquinolones and propionic acid derivatives induce inflammatory responses in vitro (2018) (7)
Simultaneous measurement of gene expression for hepatotoxicity in thioacetamide-administered rats by DNA microarrays. (2006) (7)
Occurrence of autoantibody to protein disulfide isomerase in rats with xenobiotic-induced hepatitis. (1994) (7)
Experimental Evidence of Liver Injury by BSEP-Inhibiting Drugs With a Bile Salt Supplementation in Rats. (2019) (7)
Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development. (2021) (7)
Establishment of a novel mouse model for pioglitazone-induced skeletal muscle injury. (2017) (7)
ROLES OF CYTOCHROMES P 450 1 A 2 , 2 A 6 , AND 2 C 8 IN 5-FLUOROURACIL FORMATION FROM TEGAFUR , AN ANTICANCER PRODRUG , IN HUMAN LIVER MICROSOMES (2000) (6)
Sensitive assay of trimethylamine N-oxide in liver microsomes by headspace gas chromatography with flame thermionic detection. (1999) (6)
Stereoselective S-oxidation and reduction of flosequinan in rat. (1999) (6)
[Establishment of animal models of drug-induced liver injury and analysis of possible mechanisms]. (2015) (6)
Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450. (2016) (6)
Dephosphorylation of ribosomal protein P0 in response to troglitazone-induced cytotoxicity. (2006) (6)
Interactions between Human UGT 1 A 1 , UGT 1 A 4 , and UGT 1 A 6 Affect Their Enzymatic Activities (2007) (6)
Occurrence of autoimmune antibodies to liver microsomal proteins associated with lethal hepatitis in LEC rats: effects of TJN-101 ((+)-(6S,7S,R-biar)- 5,6,7,8-tetrahydro-1,2,3,12-tetramethoxy-6,7-dimethyl-10,11- methylenedioxy-6-dibenzo[a,c]cyclooctenol) on the development of hepatitis and the autoa (1995) (6)
Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan. (1994) (6)
Accumulation of the 1-methyl-4-phenylpyridinium ion in suncus (Suncus murinus) brain: implication for flavin-containing monooxygenase activity in brain microvessels. (2001) (6)
Macrophage-derived extracellular vesicles regulate concanavalin A-induced hepatitis by suppressing macrophage cytokine production. (2020) (6)
Exploration of small RNA biomarkers for testicular injury in the serum exosomes of rats. (2020) (6)
Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis. (2015) (6)
Activities of cytochrome p450 enzymes in liver and kidney microsomes from systemic carnitine deficiency mice with a gene mutation of carnitine/organic cation transporter. (2002) (6)
Establishment of MDCKII cell monolayer with metabolic activity by CYP3A4 transduced with recombinant adenovirus. (2013) (5)
Isolation and characterization of a new cDNA clone belonging to the cytochrome P450 2C gene subfamily in hamsters. (1995) (5)
Establishment of a mouse model of troglitazone‐induced liver injury and analysis of its hepatotoxic mechanism (2019) (5)
CHARACTERIZATION OF NOVEL CYP 2 A 6 POLYMORPHIC ALLELES ( CYP 2 A 6 * 18 AND CYP 2 A 6 * 19 ) THAT AFFECT ENZYMATIC ACTIVITY (2005) (5)
Acute kidney injury model established by systemic glutathione depletion in mice (2019) (5)
Recent progress in the use of microRNAs as biomarkers for drug-induced toxicities in contrast to traditional biomarkers: A comparative review. (2021) (4)
Role of cytochrome P450-mediated metabolism and identification of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury. (2015) (4)
The house musk shrew (Suncus murinus): a unique animal with extremely low level of expression of mRNAs for CYP3A and flavin-containing monooxygenase. (2000) (4)
INVOLVEMENT OF CYP 2 E 1 AS A LOW-AFFINITY ENZYME IN PHENACETIN O-DEETHYLATION IN HUMAN LIVER MICROSOMES (1999) (3)
Oxidation of Histamine H 1 Antagonist Mequitazine is Catalyzed by Cytochrome P 450 2 D 6 in Human Liver Microsomes (1998) (3)
Strain and interindividual differences in lamotrigine‐induced liver injury in mice (2018) (2)
Title Comprehensive evaluation of variability in nicotine metabolism andCYP 2 A 6 polymorphic alleles in four ethnic populations (2017) (2)
Neutrophil depletion protects against zomepirac-induced acute kidney injury in mice. (2018) (2)
The suncus (Suncus murinus) shows poor metabolic phenotype for trimethylamine N-oxygenation. (2000) (2)
Expression of Human CYPs in Chimeric Mice with Humanized Liver (2004) (2)
A new era in the study of individual differences in drug metabolism and pharmacokinetics. (2013) (2)
Human fetal liver cytochrome P-450: capacity to form genotoxic metabolites. (1992) (2)
A Novel Polymorphic Allele of Human Arylacetamide Deacetylase Leads to Diminished Enzyme Activity (2012) (2)
MicroRNA: Regulation of P450 and Pharmacogenetics (2014) (2)
Preclinical approach for identifying drug interactions (2009) (2)
Analysis of a Skeletal Muscle Injury and Drug Interactions in Lovastatin- and Fenofibrate-Coadministered Dogs (2019) (2)
Magnolia saliciforia Maxim(タムシバ)からの新ネオリグナン,マグノサリンおよびマグノシニンの単離と構造 (1983) (2)
ゲニピンとメチルアミンから生成する青色色素 II 青色色素が生成する前の赤褐色中間体の生成機構 (1994) (2)
Preparation of a specific monoclonal antibody against human UGT1A9 and evaluation of UGT1A9 protein levels in human tissues (2012) (1)
Development of mice exhibiting hepatic microsomal activity of human CYP3A4 comparable to that in human liver microsomes by intravenous administration of an adenovirus vector expressing human CYP3A4. (2014) (1)
Strategic proposals to avoid toxic drug interactions during new drug development: molecular toxicology proposals. (1996) (1)
Hormonal regulation of the mRNA level of male-dominant cytochrome P450 (CYP2C27) in hamster livers. (1995) (1)
Characterization of human UGT2A3 expression using a prepared specific antibody against UGT2A3. (2019) (1)
Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS (2018) (1)
Current topics in drug metabolism and drug toxicity. Preface. (2011) (1)
The Study on Genetic Polymorphism of CYP2A6 (2000) (1)
Stereoselective S-oxidation of flosequinan sulfide by rat hepatic flavin-containing monooxygenase 1A1 expressed in yeast. (1994) (1)
Formation of an antibacterial metabolite from a new macrolide compound 23-O-benzyl-5-mycaminosyl-tylonolide (TMC-101), by a hepatic microsomal drug-metabolizing enzyme system. (1991) (1)
Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice. (2020) (1)
Plasma miR‐218a‐5p as a biomarker for acute cholestatic liver injury in rats and investigation of its pathophysiological roles (2021) (1)
『薬物代謝と肝障害』薬物代謝と免疫・炎症を考慮した薬物性肝障害の理解と展望 (2014) (1)
Pharmacological evidence for the involvement of ryanodine receptors in halothane-induced liver injury in mice. (2020) (1)
[Regulation of human CYP1B1 and its role in carcinogenesis and estrogen homeostasis]. (2004) (1)
[New prospectives and understanding in drug-induced liver injury considering drug metabolism and immune- and inflammation-related factors]. (2014) (1)
Expression and characterization of human fetal liver cytochrome P450 (P450IIIA7) (1992) (1)
Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate (2018) (0)
DMD059485 2109..2116 (2014) (0)
Metabolism of MPTP and accumulation of an active metabolite, MPP^+, in the brain of SUNCUS murinus (1998) (0)
Microsoft Word-1239946-file00 (2011) (0)
DMD054478 1..8 (2013) (0)
CHARACTERIZATION OF TRANSGENIC MICE CARRYING A HUMAN FETUS-SPECIFIC CYP3A7. (1998) (0)
Determination of N-acetyltransferase and cytochrome P4501A2 phenotypes in human populations by analysis of caffeine urinary metabolites: correlation to genotype of N-acetyltransferase. (1993) (0)
Importance of the use of human-derived materials and of early human ADME studies in drug development. (1998) (0)
Analysis of the pathogenesis of flucloxacillin induced liver injury in mice (2012) (0)
Polymorphic Drug Metabolism by Human CYP1A2 and N-acetyltransferase: Studies with Recombinant Chinese Hamster Cells and Analyses in Japanese Populations (1994) (0)
AMPICILLIN PRODRUGS INTERACT WITH P-GLYCOPROTEIN: IN VITRO STUDY ON SUCCESSFUL PRODRUGS USING CACO-2 CELLS (2006) (0)
Microsoft Word-1742970-file00 (2013) (0)
ROLES OF HUMAN P450 ENZYMES IN DRUG OXIDATIONS USING RECOMBINANT P450S AND HUMAN LIVER MICROSOMES (1999) (0)
329 Productton of Experimental Acute Liver Injury Model Using Multicellular Spheroids Composed of Rat Parenchymal and Non-parenchymal Liver Cells (1992) (0)
Identification and Detection of a New Polymorphic CYP2D6 Allele in a Japanese Population (1994) (0)
Animal models to predict human risk factors in drug-induced adverse drug reactions (2017) (0)
Stereoselective glucuronidation of 5-(4’-hydroxyphenyl)-5-phenylhydantoin by human UGT1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions (2007) (0)
Allyl isothiocyanate (AITC) inhibits pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation and protects against acetaminophen- and amiodarone-induced cytotoxicity (2014) (0)
SC4.3 - Cellular and animal models of idiosyncratic drug-induced liver injury (2020) (0)
MicroRNAs as potential toxicological biomarkers in drug-induced liver injury (2016) (0)
TROGILTAZONE METABOLISM AND CYTOTOXIC EFFETS (2000) (0)
Metabolic Activation of Dimethylnitrosamine(DMN) by Human CYP2E1 Expressed in O^6-Methylguanine-DNA Methyltransferase-Deficient Cells (1998) (0)
INHIBITORY EFFECTS OF THAI MEDICINAL PLANTS ON HUMAN CYTOCHROME P450 AND UDP-GLUCURONOSYLTRANSFERASE ACTIVITIES (2010) (0)
Serum microRNAs as biomarkers for hepatic sinusoidal obstruction syndrome in rats (2016) (0)
HUMAN ALPHA/BETA HYDROLASE DOMAIN CONTAINING 10 (ABHD10) IS A RESPONSIBLE ENZYME FOR HYDROLYSIS OF MYCOPHENOLIC ACID ACYL GLUCURONIDE (2010) (0)
Microsoft Word-53071850-file00 (2012) (0)
INTERSPECIES VARIATION OF CYTOCHROME P-45Q - ESTAULlSHMENT OF CELL LINES CARRYING HUMAN ENZYMES AND APPLICATION TO TOXICOLOGY TESTING (1994) (0)
Role of cytochrome P 450-mediated metabolism and identi fi cation of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury (2014) (0)
Microsoft Word-37116182-file00 (2014) (0)
Inhibition of Cytochrome P450 2C9 Expression and Activity In Vitro by Allyl Isothiocyanate (2014) (0)
METABOLIC ACTIVATION AND DRUG INDUCED HEPATOTOXICITY - THE TROGLITAZONE CASE - (2006) (0)
Microsoft Word-53791601-file00 (2012) (0)
Toxicological evaluation of the acyl glucuronide of nonsteroidal anti-inflammatory drugs (2014) (0)
Fluoroquinolones and propionic acid derivatives induce inflammatory responses in vitro (2017) (0)
S6-4 Mechanistic Approach to Idiosyncratic Drug Reactions(SYMPOSIUM 6: IDIOSYNCRATIC DRUG REACTIONS)(Proceedings of the 31st Annual Meeting) (2004) (0)
Cellular and animal models for human drug-induced liver injury (2018) (0)
IN VITRO STUDY OF THE MECHANISMS OF TERBINAFINE ASSOCIATED HEPATIC INJURY (2010) (0)
Gene expressions in F344 rat livers treated with acetaminophen or cycloheximide (TOXICOGENOMICS AND TOXICOPROTEOMICS) (GENERAL SESSION BY POSTER PRESENTATION) (Proceedings of the 30th Annual Meeting) (2003) (0)
Involvement of metabolic activation of carbamazepine in liver injury in rat (2013) (0)
THE STUDY ON CYP2A6 GENETIC POLYMORPHISM (1999) (0)
[Evaluation of phase II drug metabolizing enzymes in the discovery stage]. (2009) (0)
Metabolic Activation of Benzodiazepines by CYP 3 A 4 □ S (2009) (0)
EL-1 Polymorphisms of drug metabolism and pharmacokinetics and their association with toxicity(EDUCATIONAL LECTURE)(Proceedings of the 31st Annual Meeting) (2004) (0)
Inhibiton by EGCG of benzo[a]pyrene-induced mutations in the lung of HITEC mice. (1998) (0)
Establishment and toxicological application of a cell line expressing human CYP2E1 (1996) (0)
Study of Metabolism and Cytotoxicity of Troglitazone (2001) (0)
SPECIES DIFFERENCES IN LOCALIZATION AND ACTIVITIES OF ARYLACETAMIDE DEACETYLASE IN MOUSE, RAT, AND HUMAN (2010) (0)
An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury (2020) (0)
SPECIES DIFFERENCES IN P-GLYCOPROTEIN MEDIATED TRANSPORT IN VITRO (2004) (0)
[Recent advances in evaluation studies for drug-induced liver injury]. (2020) (0)
EXPRESSION OF RECOMBINANT HUMAN CYTOCHROME P450 (P450 OR CYP) 2A6 IN ESCHERICHIA COLI. (1998) (0)
RESPONSIBLE FOR THE STEREOSELECTIVE S-OXIDATION OF FLOSEQUINAN IN HEPATIC MICROSOMES FROM RATS AND HUMANS (1997) (0)
Regulation of Cytochrome b5 Expression by miR-223 in Human Liver: Effects on Cytochrome P450 Activities (2013) (0)
A Mechanistic View of Troglitazone Hepatotoxicity (2008) (0)
Stable expression of CYP3A4 and CYP3A7, adult and fetal-specific forms of cytochrome P450 in human liver, in CHL cells and its application to toxicological testing. (1994) (0)
Recent Progress and Prospect of Drug Metabolism/Pharmacokinetics Research Contributing to Drug Development: 医薬品開発研究を中心として (2017) (0)
Cancer Therapy : Preclinical P-Glycoprotein , CYP 3 A , and Plasma Carboxylesterase Determine Brain and Blood Disposition of themTOR Inhibitor Everolimus ( A fi nitor ) in Mice (2014) (0)
"S2-3 STRATEGIC PROPOSALS TO AVOID TOXIC DRUG INTERACTIONS DURING NEW DRUG DEVELOPMENT : MOLECULAR TOXICOLOGY PROPOSALS ( Strategy how we can learn drug-drug interaction during the development of a new drug) (1996) (0)
Microsoft Word-68931795-file00.docx (2015) (0)
TRANSCRIPTIONAL REGULATION OF HUMAN CARBOXYLESTERASE 1 A BY NUCLEAR FACTOR-ERYTHROID 2 RELATED FACTOR 2 ( NRF 2 ) (2009) (0)
THE POSSIBLE FUNCTIONS OF HUMAN FETUS-SPECIFIC CYTOCHROME P 450 ( CYP 3 A 7 ) : USING TRANSGENIC MICE CARRYING CYP 3 A 7 cDNA (2007) (0)
Genetic Polymorphism of Drug Metabolizing Enzymes and Personalized Medicine (2001) (0)
Toxicological evaluation of acylglucuronide metabolite in diclofenac-induced liver injury model in mice (2017) (0)
THE POSSIBLE FUNCTIONS OF HUMAN FETUS-SPECIFIC CYTOCHROME P450(CYP3A7): USING TRANSGENIC MICE CARRYING CYP3A7cDNA (1995) (0)
Genetic Polymorphism of Drug Metabolizing Enzymes in Humans; Approach on Basis of Molecular Biology (1997) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Tsuyoshi Yokoi?

Tsuyoshi Yokoi is affiliated with the following schools:

Tsuyoshi Yokoi's Academic­Influence.com Rankings

Tsuyoshi Yokoi's Degrees

Similar Degrees You Can Earn

Why Is Tsuyoshi Yokoi Influential?

Tsuyoshi Yokoi's Published Works

Published Works

What Schools Are Affiliated With Tsuyoshi Yokoi?

Tsuyoshi Yokoi's AcademicInfluence.com Rankings